First characterized by Loren Pickart in 1973
However, some people may experience fatigue or tiredness when they first start taking the medication
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
Animal studies have shown that T4 administration significantly improves functional recovery after traumatic brain injury, even when treatment is delayed by 24 hours post-injury
Rapid weight loss during the first trimesterif pregnancy occurs while taking GLP-1 therapycould theoretically reduce nutrient availability to a developing fetus, which is why timing and medical oversight matter
This triple receptor activity creates a powerful metabolic signalling profile affecting appetite regulation, energy expenditure, and metabolic balance